Head to Head Review: Demant A/S (OTCMKTS:WILYY) vs. Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ:ORMP) and Demant A/S (OTCMKTS:WILYY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Insider & Institutional Ownership

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Oramed Pharmaceuticals and Demant A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.57%	-5.22%
Demant A/S	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings for Oramed Pharmaceuticals and Demant A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0	1	0	0	2.00
Demant A/S	0	1	0	1	3.00

Risk and Volatility

Oramed Pharmaceuticals has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Demant A/S has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Earnings and Valuation

This table compares Oramed Pharmaceuticals and Demant A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$1.34 million	101.28	-$19.06 million	$1.26	2.71
Demant A/S	$3.25 billion	2.01	$346.11 million	N/A	N/A

Demant A/S has higher revenue and earnings than Oramed Pharmaceuticals.

Summary

Demant A/S beats Oramed Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.